Petros Pharmaceuticals Inc · OTC:PTPI
Petros Pharmaceuticals — Investor Presentation (September 2023)
10 slides from Petros Pharmaceuticals's investor presentation, Sep 7, 2023
Slide 1: Pursuing Innovation in Expanded Access to Prescription Therapeutics
Pursuing Innovation in Expanded Access to Prescription Therapeutics Nasdaq: PTPI
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation includes or incorporates forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements
Slide 3: Investment Highlights
Investment Highlights • First Mover Potential: Currently pursuing FDA approval for patent protected prescription erectile dysfunction therapy, STENDRA, for Over the Counter (OTC), nonprescription access • ED Market Opportunity: US ED Drug market estimated at $1.8B by 20281, likely to be much higher
Slide 4: Management Team Highlight
Management Team Highlight John Shulman Petros Pharmaceuticals Executive Chairman of Founder & Managing the Board Partner Principal and Founder of Juggernaut CP Greg Bradley Petros Pharmaceuticals Current Board Member President & CEO Current President, & CEO Foundation Consumer Healthcare Rx – OTC Sw
Slide 5: The ED Market Opportunity
The ED Market Opportunity Successful Approval of an ED OTC option could Significantly Expand the Market 30M US Rx Only ED Treatment Market $2,000 3x $1,786 $1,800 $1,667 R CAG $1,557 ED affects 30 million $1,600 7 . 1 % $1,454 men in the U.S.1 $1,400 $1,357 US OTC market opportunity may $1,267 $1,18
Slide 6: Current Flagship Pharmaceutical Asset
Current Flagship Pharmaceutical Asset • Distinct and patent protected • Under development for Over the Counter (OTC) designation • Potential to become the first prescription therapy available OTC in its class • Visit STENDRA.Com to learn more Please see full Prescribing Information:https://stendra.c
Slide 7: STENDRA OTC Development Program 2021-2025
STENDRA OTC Development Program 2021-2025 2025 2024 We are here FDA AUT Review 2023 FDA Meeting SHFS Review 2022 Pivotal SSS Meeting AUT – Actual Use Trial - FDA with Assesses consumer use, with FHFS w/ Meeting Technology a practitioner observer 2021 LCS w FDA Technology Type C without mediation. FD
Slide 8: Unprecedented Pathways to OTC Available
Unprecedented Pathways to OTC Available STENDRA OTC 2022 - FDA Proposed new rule development program for nonprescription or OTC is anticipated to therapies, may enable the use include a technology of technology platform Concept technologies may Technology platform include an embedded smart may be st
Slide 9: Emerging Stand-Alone Self-Care Industry
Emerging Stand-Alone Industry Currently developing patented Rx ED therapy for OTC/nonprescription designation •Recently purchased HRA Petros Perrigo •Switched Opill from Rx to OTC Pharma Rx to OTC switch Market $PTPI A Substantial Self-Care Industry amidst Pharma •Restructured Consumer Sanofi Busine
Slide 10: Opportunity to be the first U.S. company to switch a prescription ED drug to OTC
Nasdaq: PTPI • Opportunity to be the first U.S. company to successfully switch a prescription erectile dysfunction drug to over-the- counter/nonprescription designation • Developing Technology Platform that may be accommodative to future Rx to OTC switch candidates in a substantially emerging market
Petros Pharmaceuticals — Investor Presentation (September 2023) on 6ix